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Long-term outcomesAbstract Background: Gastrointestinal stromal tumours (GISTs) are the most common gas-
trointestinal sarcomas. This global, prospective registry followed patients with advanced or
localised GIST (2007–2011).
Methods: Current and evolving diagnostics, treatments and outcome measures in patients
with GIST were assessed. Eligible patients were diagnosed with advanced or localised GIST
within 15 months of registry entry. No treatment plan was prescribed, and no visit schedule
was mandated. Treating physicians recorded patient information, including tumour response,
diagnostic methods, medications, surgeries performed, mutation status and adverse events54801;
ancer.fr
c.seoul.
tis.com
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Mutational analysis
Localised
Advanced
Adjuvantleading to dose/medication changes. Survival outcomes were estimated using the
Kaplan–Meier method. Other data were analysed using descriptive statistics.
Results: The registry included 1663 patients (advanced GIST, n = 1095; localised GIST,
n = 537). Medications (e.g. tyrosine kinase inhibitor use and dosing), disease progression or
recurrence and physician assessment of response to treatment in registry patients were consis-
tent with controlled trials and prevailing clinical recommendations. In advanced GIST, esti-
mated 30-month progression-free survival (PFS) (59.8%) and overall survival (OS) (82.7%)
were higher than results from previously reported trials (40% and 70%, respectively).
Consistent with treatment guidelines, the most common initial treatments were imatinib for
advanced GIST, and complete surgical resection for localised GIST. Computed tomography
scans were the most common imaging technique used at diagnosis and follow-up. Mutation
analysis was performed at diagnosis in only 15.3% and 14.5% of patients with advanced
and localised GIST, respectively.
Conclusions: In this real-world GIST registry, patients with advanced GIST were treated with
imatinib and patients with localised GIST received surgical resection, in accordance with
prevailing clinical recommendations.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gastrointestinal stromal tumours (GISTs) are rare,
but represent the most common mesenchymal neo-
plasms of the alimentary canal [1,2]. They are derived
from malignant transformation of the interstitial cells
of Cajal, c-KIT–positive cells of neuroendocrine origin
that function as the pacemaker in peristalsis [3]. The
main drivers of GIST are somatic gain-of-function
mutations in the tyrosine kinase KIT gene [1,4,5]. The
most common sites of origin are the stomach (60%),
jejunum and ileum (30%), duodenum (5%) and colorec-
tum (<5%) [1].
Patients with GIST are categorised as having loca-
lised (resectable) or advanced (metastatic and/or locally
advanced and unresectable) disease. In advanced GIST,
inhibition of mutated c-KIT with imatinib, a tyrosine
kinase inhibitor (TKI), has substantially improved
long-term outcomes. In the preimatinib era, median
progression-free survival (PFS) and overall survival
(OS) were both <12 months [6]. With imatinib, median
PFS and OS increased to >24 months and >55 months,
respectively [7,8]. Sequential use of other TKIs (suni-
tinib and regorafenib) following development of resis-
tance to imatinib has further improved long-term
outcomes [7–12]. Surgical resection is the standard of
care for localised, primary GISTs. Adjuvant imatinib
following complete surgical resection prolongs
recurrence-free survival (RFS) in patients with higher
risk of recurrence [13,14]. The extent to which treatment
recommendations for GIST [15–20] has been imple-
mented in clinical practice, and their eﬀects in the
real-world setting, in a large patient cohort, has not been
studied previously.
The GOLD ReGISTry is a 5-year global observa-
tional registry (April 2007 to October 2011) originally
designed to collect longitudinal data on patients withadvanced GIST with the objective to assess the
real-world use of current and evolving diagnostic tech-
niques, treatment algorithms and outcomes in patients
with advanced GIST. In July 2007, a protocol amend-
ment allowed enrolment of patients with localised
GIST after positive data from an interim analysis of
the American College of Surgeons Oncology Group
(ACOSOG) Z9001 trial were reported [21].
No patients from the United States (US) or United
Kingdom (UK) were included in this registry because
separate concurrent national registries were set up in
these countries [22,23].
2. Patients and methods
2.1. General description and patient population
This 5-year global, multicenter, prospective, observa-
tional, non-interventional registry initially included only
patients with advanced GIST (metastatic, unresectable
or recurrence of previously resected disease). Patients
with localised GIST could enrol after the protocol was
amended in July 2007, following presentation of early
data from ACOSOG Z9001 [21]. All patients were diag-
nosed within 15 months of registry entry. More details
on entry criteria, registry design and analysis sets are
available in Supplementary Appendix A.
2.2. Objectives
Clinical eﬀectiveness was evaluated by Kaplan–Meier
estimates of OS, PFS and RFS. Tumour response was
reported by the treating physician (satisfactory versus
unsatisfactory). Diagnostic and treatment modalities
(including any mutation analyses or surgical procedures)
were described. Treatment duration, time from surgery
to treatment, dose/regimen changes and reasons for
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ment of other cancers and incidence of familial GIST
were longitudinally assessed. Practice patterns were
compared with the prevailing European Society of
Medical Oncology (ESMO) recommendations [15–19].
The date at which eligible diagnosis was entered into
the registry was used as the baseline for determining
duration of response, duration of treatment and
survival.2.3. Ethics
This registry complied with the ethical principles of
the Declaration of Helsinki, Good Pharmaco-
epidemiology Practice and applicable local regulations.
Written and dated informed consent was obtained from
each patient.3. Results
3.1. Baseline characteristics
Median age and median time to registry entry since
eligible GIST diagnosis were similar in the advanced
and localised GIST groups (Table 1). The most common
primary tumour sites were the small intestine and stom-
ach, respectively. At diagnosis, CT scans were the most
common imaging methods and biopsies were the most
common methods for obtaining histologic samples. Of
the 815 patients in the advanced group for whom risk
level was assessed, 18.0% had metastatic disease. In
the localised group, 484 patients had a risk assessment
performed (22.1% low, 21.5% intermediate, and 44.8%
high per modiﬁed Fletcher criteria).3.2. Patient disposition
Of 1753 patients screened for participation in this reg-
istry, 1632 (93.1%) patients from 183 sites in 34 countries
in Europe, Latin America, Asia and Canada were
enrolled and met eligibility criteria. In the advanced
(n = 1095) and localised (n = 537) GIST groups, 653
(59.6%) and 447 (83.2%) patients, respectively, completed
the registry (ie, remained in follow-up until the ﬁnal data
cutoﬀ); 432 (39.5%) and 81 (15.1%), respectively, discon-
tinued participation (Supplementary Appendix B). In
both groups, the most common reasons for discontinua-
tion were death (262 and 28 patients, respectively) and
loss to follow-up (132 and 43 patients, respectively).3.3. Treatments at diagnosis and during the registry
In the advanced GIST group, most patients (96.3%)
were treated with medication and/or surgery. Imatinib
was the most common medication at diagnosis and dur-
ing the registry period (Table 2). The most commonsurgeries were complete resection and complete removal
of metastatic lesions. Less common were partial resec-
tion, partial metastatic lesion removal and resection of
local recurrent tumour.
In the advanced group, 450 patients received surgery.
Prior to initial surgery, 132 (29.3%) patients received
TKIs. Median time between initiating TKI medica-
tion and initial surgery was 11.40 months (range,
0.56–50.50). TKI medication was given after initial
surgery in 387 (86.0%) patients. Median time between
initial surgery and start of TKI medication was
1.12 months (range, 0.03–151.79).
In the localised GIST group, surgery was the most
common initial treatment; the most common surgery
was complete resection of the primary tumour.
Imatinib was the initial medication for 204 (38.0%)
patients at diagnosis (Table 2). During the registry per-
iod, of 217 patients who received medication, the most
common medications were imatinib (n = 176, 81.1%)
and sunitinib (n = 11, 5.1%).
In the localised group, 392 patients received surgery.
For the 6 (1.5%) patients who received TKIs prior to
initial surgery, median time between initiating TKI
medication and initial surgery was 7.43 months (range
0.10–12.98). After initial surgery, 149 (38.0%) patients
received TKIs; in this group, median time between surgery
and start of TKI was 1.87 months (range 0.03–27.70).3.4. Survival outcomes
Median OS was not reached in either group (Fig. 1;
Supplementary Appendix C). Estimated 30-month OS
rates were 82.7% (95% conﬁdence interval (CI)
80.4–85.0) and 94.4% (95% CI 92.2–96.6) in the
advanced and localised GIST groups, respectively. In
the advanced GIST group, the median PFS was
40.8 months (95% CI 37.1–45.0) and the estimated
30-month PFS rate was 59.8% (95% CI 56.8–62.8). In
localised GIST, RFS is usually measured starting at
resection. Because only 353 of 537 patients had docu-
mented complete surgical resection, RFS was evaluated
using date of surgery (n = 353) and date of diagnosis
(n = 537) as baseline to determine whether RFS diﬀered
in patients with surgery. The median RFS was not
reached regardless of which start date was used, though
diagnosis typically predated surgery. Estimated
30-month RFS rates were 87.2% (95% CI 83.4–91.0)
and 85.4% (95% CI 82.1–88.7), respectively.3.5. Physician’s opinion of response to initial treatment
CT scans were used most frequently to assess tumour
response to initial treatment (67.8% and 48.8% in the
advanced and localised GIST groups, respectively,
Table 3). Physician’s opinion of tumour response was
satisfactory (SD or better) in 61.8% and 28.7% of
Table 1
Baseline characteristics.
Advanced GIST
(n = 1095)
Localised GIST
(n = 537)
Median age (range), y 59.0 (18–95) 57.0 (17–89)
Male, n (%) 638 (58.3) 262 (48.8)
Median time to registry entry since eligible GIST diagnosis (range), moa 4.24 (0.03–15.05) 4.80 (0.03–14.95)
Location of GIST primary tumour, n (%)
Oesophagus 13 (1.2) 2 (0.4)
Stomach 389 (35.5) 295 (54.9)
Small intestine 427 (39.0) 176 (32.8)
Colon 23 (2.1) 12 (2.2)
Appendix 3 (0.3) 1 (0.2)
Rectum 68 (6.2) 19 (3.5)
Peritoneum 60 (5.5) 8 (1.5)
Extra-gastrointestinal 54 (4.9) 12 (2.2)
Other 58 (5.3) 12 (2.2)
Risk assessment performed, n (%)b 815 (74.4) 484 (90.1)
Very low riskc 9 (1.1) 27 (5.6)
Low riskc 39 (4.8) 107 (22.1)
Intermediate riskc 95 (11.7) 104 (21.5)
High riskc 479 (58.8) 217 (44.8)
Metastatic diseasec 147 (18.0) 1 (0.2)
Unable to assess due to lack of mitotic countc 46 (5.6) 28 (5.8)
Methods used to determine eligible diagnosis, n (%)d
Unknown 6 (0.5) 14 (2.6)
Biopsy (total) 586 (53.5) 390 (72.6)
Surgical 315 (28.8) 339 (63.1)
Percutaneous 173 (15.8) 14 (2.6)
Endoscopic 102 (9.3) 48 (8.9)
Other 13 (1.2) 0
CT scan 799 (73.0) 312 (58.1)
Clinical evaluation 233 (21.3) 145 (27.0)
Ultrasound 212 (19.4) 87 (16.2)
Endoscopy 108 (9.9) 128 (23.8)
Laboratory values 92 (8.4) 92 (17.1)
MRI 78 (7.1) 12 (2.2)
Chest/abdominal X-ray 76 (6.9) 78 (14.5)
PET/CT fusion 67 (6.1) 8 (1.5)
FDG-PET 66 (6.0) 5 (0.9)
Endoscopic ultrasound 26 (2.4) 39 (7.3)
Laparoscopy 23 (2.1) 21 (3.9)
Other 53 (4.8) 52 (9.7)
CT, computed tomography; FDG, ﬂuoro-deoxyglucose; GIST, gastrointestinal stromal tumour; MRI, magnetic resonance imaging; PET, positron
emission tomography.
a Date of informed consent was used as registry entry.
b By size and/or mitotic count and/or metastasis for original GIST.
c The denominator for % is the number of patients for whom risk assessment was performed.
d Categories are not mutually exclusive.
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an additional 41.3% had no progression after surgery.
Unsatisfactory tumour response (i.e. lack of response)
was reported in 10.0% and 1.5%, respectively.
3.6. Drug exposure and safety
The median overall exposure to any TKI for patients
in the advanced (n = 994) and localised (n = 207) groups
who received any TKI since eligible diagnosis was
31.49 months (range, 0.07–65.38) and 19.48 months
(range, 0.26–53.13), respectively. Total time on TKItreatment exceeded 36 months in 64.8% and 19.4%,
respectively.
Safety data were collected as described in the registry
protocol. Adverse events (AEs) were not solicited during
the registry but serious AEs (SAEs) suspected to be
related to a Novartis drug were recorded. Safety analyses
included the cause of death and reasons for dose/regimen
changes and/or not taking medications as prescribed.
For any medications received during registry, AEs
leading to a dose/regimen change or a medication not
taken as prescribed were reported in 124 (11.3%) and
17 (3.2%) patients in the modiﬁed advanced (n = 1096)
Table 2
Treatments used at diagnosis and during the course of the registry.
Advanced GIST
(n = 1095)
Localised GIST
(n = 537)
Initial treatments for eligible diagnosis
Any surgeries or medication 1054 (96.3) 450 (83.8)
Any surgery 450 (41.1) 392 (73.0)
Complete resection of GIST 215 (47.8) 372 (94.9)
Partial resection of GIST 64 (14.2) 13 (3.3)
Resection of local recurrent tumour 39 (8.7) 2 (0.5)
Complete metastatic lesion removal 75 (16.7) 3 (0.8)
Partial metastatic lesion removal 54 (12.0) 0
Surgery to treat GIST-related complication 22 (4.9) 3 (0.8)
Surgery to prevent GIST-related complication 8 (1.8) 0
Other surgery 12 (2.7) 1 (0.3)
Surgery only 46 (4.2) 233 (43.4)
Any imatinib 970 (88.6) 204 (38.0)
Imatinib only 462 (42.2) 50 (9.3)
Surgery and imatinib 389 (35.5) 147 (27.4)
Any other TKI 236 (21.6) 18 (3.4)
No surgery or medication 41 (3.7) 87 (16.2)
Use of medications during the course of the registry
No medication 87 (7.9) 320 (59.6)
Any medication 1008 (92.1) 217 (40.4)
Of the patients who received any medication
Enrolled in Novartis clinical trial 57 (5.7) 41 (18.9)
Received imatinib in clinical trial 32 (3.2) 32 (14.7)
Enrolled in non-Novartis clinical trial 17 (1.7) 1 (0.5)
Non-clinical trial medication
Imatinib 951 (94.3) 176 (81.1)
Sunitinib 215 (21.3) 11 (5.1)
Other non-Novartis druga 34 (3.4) 10 (4.6)
Nilotinib 33 (3.3) 2 (0.9)
Chemotherapy 9 (0.9) 1 (0.5)
Dasatinib 2 (0.2) 1 (0.5)
Other Novartis drug 1 (0.1) 0
All data are presented as n (%).
GIST, gastrointestinal stromal tumour; TKI, tyrosine kinase inhibitor.
a The other non-Novartis drug is most likely regorafenib, but this information was not speciﬁcally collected.
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(Supplementary Appendix D). Of these, the most com-
mon AEs in the advanced group (each in 61.2%
patients) were fatigue, peripheral oedema, rash,
hand-foot syndrome and diarrhoea. In the localised
GIST group, peripheral oedema (0.6%) and nausea
(0.4%) were the only AEs reported in >1 patient.
SAEs suspected as related to imatinib were rare,
reported in 5 (0.5%) and 2 (0.4%) patients in the
advanced and localised GIST groups, respectively. No
individual SAE occurred in >1 patient in either group.
Deaths were reported in 262 (23.9%) and 28 (5.2%)
patients, respectively; 220 and 17 deaths, respectively,
were due to disease progression.3.7. Non-GIST malignancies and patient/family history of
GIST
Before registry entry, non-GIST malignancies were
reported in 6.7% and 6.0% of patients in the advancedand localised GIST groups, respectively
(Supplementary Appendix E). After registry entry,
2.3% and 1.3% of patients, respectively, were diagnosed
with non-GIST malignancies. No non-GIST cancer type
occurred in >1.5% of patients at diagnosis or during the
registry. At diagnosis, 0.5% of patients in the advanced
group and 0.9% of patients in the localised group had a
history of neuroﬁbromatosis. Few family members had
GIST prior to registry entry (0.3% and 0.2%, respec-
tively) or during registry period (0.2% and 0%,
respectively).3.8. Comparison of treatment patterns with clinical
guidelines
Registry data were compared with ESMO recommen-
dations in eﬀect during registry [15–19]. Overall, most
clinical practices (including ﬁrst- and second-line treat-
ment regimens, surgical procedures and disease moni-
toring) followed these recommendations (Table 5).
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Fig. 1. Kaplan–Meier analysis of survival outcomes for the (A) advanced and (B) localised GIST groups.
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was performed in <15% of patients at diagnosis in both
the advanced and localised GIST groups (Table 6). KIT
exon 11 mutation was the most common genotype
occurring in 50% of patients in both groups.
Additional comparisons of registry data with ESMO
recommendations are presented in Supplementary
Appendix F.4. Discussion
Patients included in clinical trials are selected and do
not include all clinical presentations and situations
observed in the real-world setting. For this reason, an
analysis of the impact of treatment in unselected popu-
lations of patients is important to assess the beneﬁt of
a therapeutic strategy.
Table 3
Methods to determine tumour response to initial treatment.
Advanced GIST
(n = 1095)
Localised GIST
(n = 537)
CT scan 742 (67.8) 262 (48.8)
Clinical evaluation 268 (24.5) 199 (37.1)
Unknown/NA 210 (19.2) 146 (27.2)
Ultrasound 103 (9.4) 76 (14.2)
Laboratory values 87 (7.9) 60 (11.2)
FDG-PET 55 (5.0) 8 (1.5)
PET/CT fusion 48 (4.4) 12 (2.2)
MRI 39 (3.6) 4 (0.7)
Biopsy (total) 23 (2.1) 16 (3.0)
Surgical 18 (1.6) 15 (2.8)
Percutaneous 4 (0.4) 0
Endoscopic 1 (0.1) 1 (0.2)
Other 0 0
Chest/abdominal X-ray 18 (1.6) 26 (4.8)
Endoscopy 15 (1.4) 22 (4.1)
Endoscopic ultrasound 3 (0.3) 2 (0.4)
Laparoscopy 0 1 (0.2)
Other 11 (1.0) 20 (3.7)
All data are presented as n (%).
CT, computed tomography; FDG, ﬂuoro-deoxyglucose; GIST, gas-
trointestinal stromal tumour; MRI, magnetic resonance imaging; NA,
not available; PET, positron emission tomography.
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ReGISTry provides a large set of data on real-world
treatment of GIST at the advent of the TKI era. In this
registry, management of patients with GIST was consis-
tent with ESMO recommendations [15–20]. The most
common initial treatments were surgery for localised
GIST and imatinib 400 mg/day for advanced GIST.
However, no surgery was reported for 30% of patients
with localised GIST as initial therapy, despite surgical
resection being the standard of care for this population.
This could have been due to the way data were collected
upon enrolment (i.e. for some patients, surgeries may
have been performed, but not designated as the treat-
ment associated with the initial/eligible diagnosis of
GIST). Few patients had mutation analysis performedTable 4
Physician’s opinion of tumour response.
At initial treatmenta
Response to treatment Advanced GIST
(n = 1095)
Not applicablec 126 (11.5)
Not satisfactory (lack of response) 109 (10.0)
Stable disease or better 677 (61.8)
No progression of disease after surgery N/A
Unable to assess 114 (10.4)
Unknown 69 (6.3)
Missing 0
All data are presented as n (%).
GIST, gastrointestinal stromal tumour.
a Treatment that has been entered as initial treatment for the eligible diagn
once per patient and values add up to 100% of patients.
b Tumour response any time during the registry. Values were not mutua
c Eligible diagnosis newly made and no treatments occurred prior to regat diagnosis, consistent with the prevailing clinical prac-
tice prior to the release of the 2008 ESMO guidelines.
Availability of mutation analysis data remains a major
limitation in most places worldwide. Regardless, the
proportion of patients with each mutation type was con-
sistent with results from other registries and clinical tri-
als [7,9,23–25]. Dosing of imatinib (the most commonly
prescribed TKI in this registry and the only one indi-
cated in the ﬁrst-line or adjuvant treatment) and meth-
ods for monitoring tumour response were consistent
with ESMO guidelines.
Registries from Poland, USA, Switzerland, UK,
Sweden, Iceland, Spain and Taiwan have evaluated
patients with GIST, both prior to the widespread use
of imatinib [26–28] and more recently [22,23,29–32].
Most of these, except the Taiwanese registry [32],
included fewer patients than the GOLD ReGISTry.
These national registries included all patients with
GIST in a given country, thus allowing calculations of
the incidence of GIST for that country. In contrast,
the GOLD ReGISTry was multinational, but not all
patients with GIST in each country were enrolled;
hence, epidemiological calculations cannot be per-
formed. A nonproﬁt organisation (LifeRaft Group) also
conducted a large, multinational registry (n = 1215) [25].
In all of these real-world studies, median age was simi-
lar, approximately 50% of patients were male, and
KIT exon 11 mutations were the most prevalent GIST
genotype (57–63%) [22,23,25–31]. These characteristics
are consistent with those in the GOLD ReGISTry.
Most of these registries did not report diagnostic meth-
ods or treatments prescribed. The US registry (n = 882)
reported that 87% of patients with localised GIST and
50% of those with advanced GIST had surgeries [23].
These values are slightly higher than those reported in
the GOLD ReGISTry (73.0% and 41.1%, respectively).
Furthermore, our results indicate a higher proportion
of patients with advanced disease were treated with
TKIs as initial treatment than in the US registry (89%At least once during the registryb
Localised GIST
(n = 537)
Advanced GIST
(n = 1095)
Localised GIST
(n = 537)
113 (21.0) 231 (21.1) 213 (39.7)
8 (1.5) 318 (29.0) 37 (6.9)
154 (28.7) 941 (85.9) 304 (56.6)
222 (41.3) N/A 278 (51.8)
18 (3.4) 247 (22.6) 88 (16.4)
18 (3.4) 0 0
4 (0.7) 0 0
osis according to the case report form; each category was counted only
lly exclusive, so the sum is >100%.
istry entry.
Table 5
Comparison of registry data versus ESMO guidelines.
Advanced GIST (n = 1095) Localised GIST (n = 537)
KIT Exon 9
(n = 18)
No KIT Exon 9
(n = 1077)
Low risk
(n = 134)
Int. risk
(n = 104)
High risk
(n = 217)
Total (n = 537)
First-line treatment (advanced)/adjuvant treatment (localised) ESMO recommends imatinib 400 mg/d; 800 mg/d if KIT
exon 9
ESMO recommends imatinib 400 mg/d for 3 years for patients with
high riska
Imatinib 800 mg/d 0 26 (2.4) 0 0 0 0
Imatinib >400 to <800 mg/d 1 (5.6) 15 (1.4) 0 0 0 0
Imatinib 400 mg/d 17 (94.4) 895 (83.1) 4 (8.5) 15 (22.1) 72 (55.4) 119 (33.7)
Imatinib <400 mg/d 0 9 (0.8) 0 0 0 0
Sunitinib 0 14 (1.3) 0 0 0 0
Investigational productb 0 31 (2.9) 1 (1.1) 1 (1.5) 8 (6.2) 11 (3.1)
No medication 0 87 (8.1) 85 (90.4) 52 (76.5) 50 (38.5) 223 (63.2)
Median duration of imatinib treatment (range), d N/A 0 (0–1484) 0 (0–1296) 312.5(0–1535) 0 (0–1535)
Monitoring at any time since diagnosis ESMO recommends CT scans; MRI and FDG-PET can be used in certain situations
CT scan 18 (100) 1041 (96.7) 119 (88.8) 96 (92.3) 209 (96.3) 502 (93.5)
FDG-PET 7 (38.9) 129 (12.0) 6 (4.5) 10 (9.6) 13 (6.0) 32 (6.0)
MRI 2 (11.1) 126 (11.7) 7 (5.2) 5 (4.8) 14 (6.5) 32 (5.6)
Otherc 14 (77.8) 805 (74.7) 122 (91.0) 84 (80.8) 193 (88.9) 472 (87.9)
Second-line treatment (progression [advanced]/ recurrence [localised]) ESMO recommends imatinib 800 mg/d if progression;
sunitinib as second-line treatment
No speciﬁc guidelines in place for second-line adjuvant treatment
Progression/recurrence
Number progressed/recurred n = 17 n = 524; n = 8; n = 4; n = 23 n = 49
Number changed medication 15/17 (88.2) 325/524 (62.0) 2/94 (2.1)d 0/68 11/130 18/353
Imatinib >800 mg/d 0 1 (0.3) 0 0 0 0
Imatinib 800 mg/d 7 (46.7) 132 (40.6) 0 0 2 (18.2) 3 (16.7)
Imatinib >400 to <800 mg/d 2 (13.3) 36 (11.1) 0 0 0 0
Imatinib 400 mg/d 0 6 (1.8) 1 (50.0) 0 2 (18.2) 3 (16.7)
Imatinib <400 mg/d 0 30 (9.2) 0 0 3 (27.3) 3 (16.7)
Sunitinib 3 (20.0) 101 (31.1) 1 (50.0) 0 2 (18.2) 4 (22.2)
Investigational productb 3 (20.0) 19 (5.8) 0 0 2 (18.2) 5 (27.8)
No progression N/A
Number not progressed n = 1 n = 553
Number changed medication 0 48 (8.7)
Imatinib 800 mg/d 0 5 (10.4)
Imatinib >400 to <800 mg/d 0 0
Imatinib 400 mg/d 0 2 (4.2)
Imatinib <400 mg/d 0 34 (70.8)
Sunitinib 0 4 (8.3)
Investigational productb 0 3 (6.3)
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itoring most frequently included CT scans. Estimated
30-month OS rates were similar in the GOLD
ReGISTry and the LifeRaft registry (90% for localised
GIST and 80% for advanced GIST) [25]. In the Polish
registry for advanced GIST, the 30-month OS rate was
slightly lower (70%); however, median PFS
(37.5 months) was similar to that of GOLD ReGISTry
(40.8 months) [31].
Survival outcomes were higher in patients with
advanced disease in the GOLD ReGISTry than in previ-
ous clinical trials of patients with advanced GIST. In
registration studies, median PFS and OS were
18.9 months and 49.0 months, respectively, for patients
with advanced GIST receiving imatinib 400 mg/d [33].
Estimated 30-month PFS and OS were approximately
40% and 70% in large clinical trials of imatinib (com-
pared with 59.8% and 82.7%, respectively, in this reg-
istry) [7,9,24]. Median PFS for patients with advanced
GIST in this registry was substantially higher than in
the prospective BFR14 trial, which began enrolling
patients in 2002 (40.8 months versus 29.7 months)
[34,35]. However, it should be noted that clinical trials
deﬁne baseline considering the time of study entry, not
diagnosis. The survival results would likely be longer if
the time of initial diagnosis were used as baseline. It is
likely that more patients are treated earlier in the disease
course and have less extensive disease than patients in
the early 2000s. Because the advanced GIST group in
this registry likely had less extensive, less prolonged dis-
ease than those enrolled in early clinical trials, it is not
surprising that patients in the registry had a median
PFS much longer than that reported in BFR14 [7–10].
Furthermore, the less stringent monitoring in the reg-
istry and less frequent follow-ups (at least twice per
year) compared with controlled clinical trials may have
contributed to the longer PFS results. Less frequent
monitoring could allow more time to elapse before pro-
gression was recorded, but would not necessarily indi-
cate that the progression event occurred later. Further,
in some patients with advanced disease, diagnosis was
reassigned after registry enrolment such that there were
months between enrolment and eligible diagnosis.
Because eligible diagnosis was used as baseline, this
may have skewed the results to shorter PFS.
In patients with localised GIST, survival outcomes
from the GOLD ReGISTry were similar to large clinical
trials in this population. Here, estimated 30-month OS
and RFS were 94.4% and 85.4%. In clinical trials, these
values were approximately 96–98% and 83–87%, respec-
tively [13,14]. These similarities may reﬂect that patients
with localised disease entered the registry at or near the
time of original diagnosis of GIST, which was similar to
eligibility criteria for adjuvant clinical trials.
Results from the GOLD ReGISTry document that
long-term outcomes for patients with GIST in the
Table 6
Mutational analyses performed at original/eligible diagnosis.
Advanced GIST (n = 1095) Localised GIST (n = 537)
Original diagnosis Eligible diagnosis During registry Original/eligible diagnosis During registry
Mutational analysis performed 144 (13.2) 90 (8.2) 105 (9.6) 78 (14.5) 21 (3.9)
Results obtaineda 131 (91.0) 84 (93.3) 92 (87.6) 72 (92.3) 18 (85.7)
Of the patients with mutation analysis results
KIT 108 (75.0) 68 (75.6) 69 (65.7) 55 (70.5) 13 (61.9)
Exon 9 14 (9.7) 10 (11.1) 13 (12.4) 9 (11.5) 1 (4.8)
Exon 11 78 (54.2) 42 (46.7) 54 (51.4) 40 (51.3) 11 (52.4)
Exon 13 2 (1.4) 2 (2.2) 1 (1.0) 2 (2.6) 1 (4.8)
Exon 14 1 (0.7) 0 0 1 (1.3) 0
Exon 17 1 (0.7) 0 1 (1.0) 0 0
Other 12 (8.3) 13 (14.4) 0 3 (3.8) 0
PDGFRa 10 (6.9) 8 (8.9) 9 (8.6) 12 (15.4) 3 (14.3)
Exon 12 3 (2.1) 3 (3.3) 0 2 (2.6) 0
Exon 18 6 (4.2) 4 (4.4) 9 (8.6) 8 (10.3) 3 (14.3)
Other 1 (0.7) 1 (1.1) 0 2 (2.6) 0
Wild type 12 (8.3) 7 (7.8) 10 (9.5) 5 (6.4) 2 (9.5)
Double mutation 1 (0.7) 1 (1.1) 5 (4.8) 0 0
All data are presented as n (%).
GIST, gastrointestinal stromal tumour; PDGFRa, platelet-derived growth factor receptor alpha.
a The remaining mutation analyses were not evaluable.
2432 C.H. Barrios et al. / European Journal of Cancer 51 (2015) 2423–2433real-world setting have improved substantially since
TKIs entered the treatment landscape. Areas of ongoing
clinical research involve determining the optimal dura-
tion of adjuvant treatment for localised GIST and eval-
uating novel agents targeting diﬀerent molecular
pathways to better control the disease.Authors’ contributions
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